Novo Nordisk filed suit against another semaglutide compounder on Friday, bringing its total number of cases to 50. Both Novo Nordisk and Eli Lilly have launched legal campaigns against medical spas, weight loss clinics and compounding pharmacies marketing their own versions of blockbuster weight loss and diabetes drugs. In a win for compounders last...

Novartis used one of its priority review vouchers (PRV) to speed the September approval of Kisqali in early breast cancer, the FDA said Monday. The FDA did not disclose where this PRV came to Novartis from, but the Swiss biotech has publicly disclosed an industry-leading seven PRVs, three of which were acquired on the open market for between $21 million...

Eli Lilly plans to invest £279 million ($364 million) in the UK as part of a new government partnership in which the drugmaker will bring its Gateway Labs overseas for the first time. The pharmaceutical giant also signed a memorandum of understanding with the UK’s Department of Health and Social Care, the Department for Science, Innovation and Technology,...

Private equity firms TPG and Blackstone are working on a potential deal to buy Brent Saunders-led eye care company Bausch + Lomb, the Financial Times reports. Citing “people familiar with the matter,” FT wrote Monday that the groups had already expressed interest in buying Bausch + Lomb before it was publicly listed in 2022. Its stock $BLCO rose about...

GSK announced another batch of positive data from its respiratory program with the investigational drug depemokimab, this time in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Both the Phase 3 ANCHOR-1 and ANCHOR-2 trials met the co-primary endpoints: the total endoscopic nasal polyp score at 52 weeks and mean nasal obstruction score...

The full results from Pfizer’s pivotal study of its Duchenne muscular dystrophy gene therapy show patients saw no significant functional benefit one year after receiving the therapy despite the expression of mini-dystrophin. In the Phase 3 study known as CIFFREO, 64 participants received Pfizer’s experimental therapy called fordadistrogene movaparvovec,...